Regulatory risk loci link disrupted androgen response to pathophysiology of Polycystic

Ovary Syndrome

Jaya Srivastava and Ivan Ovcharenko*

Division of Intramural Research, National Library of Medicine, National Institutes of Health,

Bethesda, MD, 20892, USA.

* To whom correspondence should be addressed: ovcharen@nih.gov

Keywords: Polycystic Ovary Syndrome (PCOS); regulatory genomics; enhancer variants; deep

learning, artificial intelligence; disease-causal noncoding variants

Abstract

A major challenge in deciphering the complex genetic landscape of Polycystic Ovary Syndrome (PCOS) lies in the limited understanding of how susceptibility loci drive molecular mechanisms across diverse phenotypes. To address this, we integrated molecular and epigenomic annotations from proposed causal cell-types and employed a deep learning (DL) framework to predict cell-type-specific regulatory effects of PCOS risk variants. Our analysis revealed that these variants affect key transcription factor (TF) binding sites, including NR4A1/2, NHLH2, FOXA1, and WT1, which regulate gonadotropin signaling, folliculogenesis, and steroidogenesis across brain and endocrine cell-types. The DL model, which showed strong concordance with reporter assay data, identified enhancer-disrupting activity in approximately 20% of risk variants. Notably, many of these variants disrupt TFs involved in androgen-mediated signaling, providing molecular insights into hyperandrogenemia in PCOS. Variants prioritized by the model were more pleiotropic and exerted stronger downregulatory effects on gene expression compared to other risk variants. Using the IRX3-FTO locus as a case study, we demonstrate how regulatory disruptions in tissues such as the fetal brain, pancreas, adipocytes, and endothelial cells may link obesity-associated mechanisms to PCOS pathogenesis via neuronal development, metabolic dysfunction, and impaired folliculogenesis. Collectively, our findings highlight the utility of integrating DL models with epigenomic

32   data to uncover disease-relevant variants, reveal cross-tissue regulatory effects, and

33   refine mechanistic understanding of PCOS.

35   **Keywords**

36   Polycystic Ovary Syndrome (PCOS); regulatory genomics; enhancer variants; deep

37   learning, artificial intelligence; disease-causal noncoding variants

Introduction

Polycystic Ovary Syndrome (PCOS) is a multifactorial endocrine disorder characterized by abnormal LH:FSH (Luteinizing hormone: Follicle Stimulating hormone) ratios and elevated androgen levels, leading to anovulation, polycystic ovaries, and various hyperandrogenism-related comorbidities (1–3). The reproductive abnormalities in PCOS stem from disruptions in the hypothalamic-pituitary-gonadal (HPG) axis, which also contributes to other conditions like oligomenorrhoea, ovarian insufficiency, infertility, hyper- and hypogonadism, and endometriosis (4). This overlap in clinical features complicates PCOS diagnosis, prompting the establishment of multiple diagnostic criteria by the NIH, Rotterdam, and the Androgen Excess and PCOS Society. Based on a consensus, diagnosis relies on clear indications of hyperandrogenism, polycystic ovarian morphology and ovulatory dysfunction (3,5).

Decades of research on molecular mechanisms underlying the disease have identified impaired folliculogenesis and enhanced steroidogenesis in theca and granulosa cells (GCs) as key contributors to PCOS development (6). These pathways are spatiotemporally regulated by LH and FSH, secreted by the pituitary gland in response to hypothalamic Gonadotropin Release Hormone (GnRH) based stimulation (7). Moreover, PCOS often coincides with hyperinsulinemia, though the molecular origins of the association between the two is still being investigated. Hyperinsulinemia worsens

hyperandrogenism by affecting adrenal androgen production and reducing sex hormone-

binding globulin (SHBG) levels in the liver (8) and may also contribute to the metabolic

co-morbidities such as obesity, type-II diabetes and liver dysfunction (3,9).

The genetic basis of PCOS is thought to involve impaired regulation of the HPG axis (10).

Polymorphisms in genes coding for kisspeptin (Kiss1, an upstream regulator of GnRH),

GnRH receptor, Anti-Mullerian Hormone (AMH), LH, FSH, and their receptors have been

linked to impaired signaling in PCOS patients (11,12). However, except for *AMHR*, no

functional studies directly connect these polymorphisms to the PCOS phenotype (13).

Twin studies suggest an estimated 80% heritability [13], highlighting the need for

detailed investigations into the molecular mechanisms underlying PCOS etiology (14).

PCOS genome-wide association studies (GWAS) across diverse populations have

identified novel disease loci, including plausible candidates such as *FSHR, FSHB*, and

LHCGR, in addition to several others with no direct association with disease phenotypes

(10). Variants in the loci *of THADA, DENND1A, IRF1, FTO* etc., have significant correlations

with the disease manifestation but have not been contextually studied. On the other

hand, polymorphisms in reproductive hormone receptors, including androgen (AR) and

estrogen receptors (*ESR1/2*), have been implicated in PCOS phenotypes (15,16);

however, these associations have not been identified in GWAS studies. These

observations align with the omnigenic model of complex trait regulation, where core

genes directly influence the phenotype, while peripheral genes contribute through cell-

type-specific regulatory networks (17). Variants exert their net impact through complex

genomic and epigenomic interactions, manifesting as GWAS association signals. This

highlights the need for further investigation into the regulatory networks governing

phenotypic complexity of PCOS. In this context, several isolated studies offer insights into

the involvement of GWAS-identified genes in PCOS pathophysiology (10). For instance,

studies show that *ERBB4* and *GATA4* regulate folliculogenesis (18,19), *ZNF217* regulates

androgen production in theca cells (20), and *HMGA2* promotes granulosa cell

proliferation (21). Interestingly, some genes exhibit pleiotropy depending on cell-type

context; *HMGA2* also regulates adipogenesis (22), and FSH influences bone density and

adipose mass (4). These findings suggest that PCOS-associated variants across multiple

loci impact different cell-types through hitherto unexplored molecular mechanisms,

contributing to phenotypic comorbidities.

In this study, we performed a functional assessment of PCOS susceptibility loci by

integrating epigenomic data, functional assays, and a deep learning (DL)-based approach

to identify causal single nucleotide variants (SNVs) across eleven disease-associated cell

types. We further investigated their potential influence on the molecular mechanisms

underlying PCOS etiology. This approach facilitated the identification of key transcription

factors (TFs) involved in folliculogenesis, androgen-mediated signaling, and ovarian

development, whose binding sites are predicted to be disrupted by causal variants. Using

the well-characterized regulatory locus of *IRX3*, we demonstrate how DL models

combined with prior knowledge of key PCOS TFs can effectively prioritize causal variants.

Results

A majority of PCOS risk SNVs lie in regulatory regions and are enriched in

neuroendocrine cell-types

To conduct a comprehensive analysis of the regulatory features of PCOS risk loci, we

identified 91 single nucleotide variants (SNVs) from twelve GWAS studies (Table S1). This

set was expanded to 1,472 SNVs, referred herein as pcosSNVs, by including variants in

linkage disequilibrium (LD) with GWAS-identified variants across all superpopulations

(African, American, South and East Asian, European) with an $r^2 \geq 0.8$, obtained from SNiPA

(23). Adjacent variants within 100kb were merged to define 50 genetic loci, named based

on the nearest gene and/or previously associated genes in the literature (Figure 1A, Table

S2). Most of these variants are located within intronic regions, with the highest density

observed in the *DENND1A* and *AOPEP* loci (Figure 1A). We then assigned target genes

using the ENCODE-rE2G model (https://github.com/EngreitzLab/ENCODE_rE2G) that

predicts enhancer-gene interactions across various cell types by integrating enhancer

activity, 3D chromatin interactions, and DNase I hypersensitivity maps. Using a threshold

of 0.8 for the rE2G score predicted from the logistic regression model, we obtained 97

target genes (Table S3), many of which were not previously linked to PCOS. These genes

are significantly enriched in pathways related to cell development, differentiation, and

apoptosis (hypergeometric p-value 10^{-6}, Figure 1B), highlighting their potential roles in

the biological mechanisms underlying the five developmental stages of folliculogenesis

in oocytes and granulosa cells (24).

The diverse phenotypic comorbidities associated with PCOS typically manifest as either

metabolic or reproductive abnormalities. To investigate potential differences between

these subtypes, we categorized pcosSNVs into metabolic or reproductive groups based

on two defined criteria: (1) trait descriptions provided in the GWAS summary statistics

(Table S1), and (2) alignment of phenotypic characteristics reported in the respective

GWAS with known subtype-specific features—namely, elevated AMH, LH, and SHBG

levels for reproductive, and high BMI, insulin, or glucose levels for metabolic—as

described in prior studies (25,26). Based on the sub-phenotype associations of GWAS

susceptibility variants, we classified fifteen loci as metabolic and sixteen as reproductive

(Table S4). To elucidate the regulatory mechanisms distinguishing the two subtypes, we

examined the differential enrichment of TFBSs in each subtype (Figure S1A, Methods).

The metabolic pcosSNVs showed significant enrichment for TFBSs of NR1D1 and *RXRB*,

which regulate adipocyte differentiation (27,28), and steroid hormone nuclear receptors

RXRB, and *THRA* (28) (binomial p-value < 0.01 vs reproductive pcosSNVs). Interestingly,

binding sites of TFs involved in the development and differentiation of GCs during

folliculogenesis, such as *CPEB1* and *FOXL2*, are enriched in the metabolic subtype. This

suggests their role in also driving metabolic abnormalities associated with PCOS, aligning

with previous observations where CPEB1 has also been shown to associate with obesity

(29). Conversely, the reproductive subtype is enriched for TFBSs of *NR5A1*, and *NR1H4*

(binomial p-value < 0.01 vs metabolic pcosSNVs), all of which have well-documented

roles in steroidogenesis and folliculogenesis (30,31). Furthermore, the two subtypes are

enriched for variants from distinct GWAS trait groups, correlating with their phenotypic

traits (Figure S1B, Methods). For example, reproductive subtype variants exhibit

significant enrichment for endocrine traits like endometriosis and uterine fibroids

(binomial p-value < 10^{-15} vs pcosSNVs), while metabolic subtype variants show significant

enrichment for obesity, BMI, and cholesterol (>5-fold, binomial p-value < 10^{-30} vs

pcosSNVs).

We next investigated the functional impact of pcosSNVs through their association with

changes in gene expression characterized by the GTEx consortium (32). Among 1,472

pcosSNVs, 832 overlapped with cis-eQTLs, termed eVariants (Table S5). Two-thirds of

these pcosSNVs are shared across multiple cell-types (we use the term cell-types herein

synonymously with tissues defined in GTEx), meaning they influence gene expression in

multiple cell types. In contrast, the remaining variants, such as those in the *FSHR* and

ERBB4 loci, are cell-type specific (Figure S2a). The number of target genes scaled almost

linearly with the number of affected cell types (Spearman correlation: 0.71, Figure S2b),

suggesting that shared eQTLs may contribute to distinct cell-type specific regulatory

networks by regulating different genes in different cell-types. Notably, eVariants in the

locus of the GATA4 gene were linked to 39 genes across 49 cell types (Figure S2b, Table

S6). 4% of eVariants targeted long non-coding RNAs (Table S5), suggesting their role as

potential trans-eQTLs (33). Meanwhile, the remaining 640 pcosSNVs that were not

identified as GTEx eVariants belong to 18 susceptibility loci, including that of *CNTNAP5*,

ASIC2, and *CDH1*, (Table S6), likely due to low target gene expression or restricted

function in specific cell states or developmental stages in the dynamic transcription

landscape that not captured in bulk tissue analysis (32,34). These pcosSNVs may play key

spatiotemporal roles in mediating GnRH response in the hypothalamus, pituitary

regulation, and follicular phase progression in PCOS (32).

We also examined the enrichment of PCOS eVariants across GTEx cell types. Compared

to a randomly selected set of 832 eQTLs (excluding PCOS eVariants), PCOS eVariants were

found to be enriched in brain cell types, reproductive hormone-producing tissues such as

the ovary and adrenal gland, as well as hormonally influenced tissues like the breast and

prostate (binomial p-value < 0.001, Figure 1C). Since many PCOS eVariants are shared

across cell-types, they likely influence regulatory networks by mediating interactions

between cell-type-specific and ubiquitous transcription factors (TFs), thereby invoking

cell-type-specific regulatory pathways that contribute to distinct phenotypic outcomes

in different cellular contexts (35). For example, *PPARG*, a susceptibility locus, plays a

central role in regulating lipid metabolism, adipocyte differentiation, gluconeogenesis,

folliculogenesis, and steroidogenesis through multiple TFs that are critical regulators of

these biological processes (www.kegg.jp/pathway/map=map03320) (36,37). This

suggests that causal variants within this locus may contribute to distinct phenotypic

outcomes through pleiotropic effects across multiple cell types. Given these

complexities, investigating disease-causal variants and their cell-type-specific effects on

downstream signaling pathways may help elucidate the mechanisms underlying the

diverse phenotypic manifestations of PCOS.

A deep learning model for prioritizing disease causal variants across causal cell-types

The challenge of characterizing the cell-type-specific impact of thousands of

susceptibility variants in complex traits and diseases has led to the development of

computational approaches for inferring causal variants. DL models have been particularly

effective in predicting variant effects on gene regulation by integrating diverse cell-type-

specific epigenomic features (38,39). We previously developed a convolutional neural

network based DL model, TREDNet, which can predict the effects of non-coding variants

on enhancer activity (40). This two-phase DL model was demonstrated as a successful

approach in prioritizing causal variants of type 2 diabetes and autism (40,41). Building on

its success, we applied TREDNet to investigate the regulatory mechanisms underlying

PCOS.

We adapted TREDNet to predict allele-specific enhancer activity of PCOS-associated

SNVs (pcosSNVs) across causal cell types implicated in PCOS. Based on the biological

origins of folliculogenesis, androgenesis, and signaling pathways involving SHBG, insulin

signaling, and adipogenesis that are known to be disrupted PCOS, we identified eleven

causal cell types for analysis with available epigenomic profiles: KGN (used as a proxy for

granulosa cells due to limited epigenomic data from primary granulosa cells), ovary, fetal

brain, adrenal gland, pancreas, adipocytes, liver, brain microvascular endothelial cells

(BMEC), mammary epithelial cells, and human umbilical vein endothelial cells (HUVEC).

In the absence of epigenomic profiles from the pituitary and hypothalamus, we included

fetal brain, and selected BMEC, mammary epithelial cells, and HUVEC as granulosa cell

proxies based on their epithelial or endothelial characteristics and similar H3K27ac

profiles (Jaccard similarity index, Table S7) (42). Additionally, we incorporated WTC11, a

developmental cell line, to capture causal variants active during early development, as

fetal development has been implicated in PCOS onset later in life (43). We trained our

model using cell-type-specific putative enhancers identified by co-occurrence of the

H3K27ac histone modification with DNase hypersensitive sites (DHS), as proxies for

active enhancers (Table S8, Methods). The DL models demonstrated robust

performance, achieving an area under the receiver operating characteristic curve

(auROC) ranging from 0.9 to 0.98 and an area under the precision-recall curve (auPRC)

ranging from 0.54 to 0.84 across the eleven cell types (Figure 2A).

To evaluate TREDNet's ability to identify causal variants, we examined the correlation

between TREDNet-predicted differences in allele-specific enhancer activity and those

determined through a massively parallel reporter assay (MPRA) in the developing human

brain and stem cell-derived adipocytes using our model trained on fetal brain and

adipocytes (44,45). We compared allele-specific TREDNet scores across all assayed

alleles and those showing significant changes in reporter activity (Methods) and

observed a significantly higher fold change in TREDNet scores for the latter group (Mann-

Whitney test p-value = 0.001 for adipocytes and 10^{-5} for fetal brain, Figure 2B). These

findings highlight TREDNet's robustness in predicting causal variants across different cell

types.

Next, we evaluated the impact of pcosSNVs within active regulatory regions across the

eleven selected cell-types, scoring both reference and risk alleles in all cell-type-specific

models (Methods). For pcosSNVs located in active regulatory regions marked by

H3K4me1, H3K27ac, or DNase/ATAC-Seq, we classified strengthening alleles as those

with scores below the threshold (determined at 10% FDR) for the reference allele and

above for the risk allele, while damaging alleles followed the opposite criterion. Applying

this approach, we identified 309 pcosSNVs with predicted allelic differences in activity,

termed reSNVs (Table S9). These reSNVs were significantly enriched in conserved

elements compared to both pcosSNVs and 13 million common SNVs from the 1000

Genomes catalog (binomial p-value = 0.0002 and 10^{-9}, respectively, Figure 2C).

To assess the regulatory impact of reSNVs, we examined the enrichment of TFBSs. The

regulatory effect of a TF was quantified by comparing the density of its binding motifs

overlapping with reSNVs to a background set of control SNVs. Specifically, we quantified

the abundance of transcription factor binding sites (TFBSs) affected by these variants and

compared it to a control set of TFBSs corresponding to 71,000 SNVs located within 100

kb of pcosSNVs (Methods). This localized background enabled us to investigate the

regulation of target genes within the context of PCOS-specific biological processes,

particularly for ubiquitously expressed genes. Several TFs showed significant enrichment

at reSNV loci, including *FOXA1*, a pioneer factor in estrogen and androgen signaling (46);

LHX4, involved in pituitary development (47); *NHLH2*, associated with GnRH signaling

(48); *WT1*, a regulator of granulosa cell proliferation (49); PLAG1, involved in oocyte

reserve maintenance (50); and *NR4A1*, which regulates steroidogenesis (51)

(hypergeometric p-value < 10^{-2}, Figure 2D). Notably, we observed a 2.6 fold enrichment

of PPARG binding sites, a significant finding given PPARG's role as a known susceptibility

locus for PCOS. We also found enrichment of TFs associated with neuronal signaling, such

as TBX21, POU6F1, and NKX6.2. While not previously linked to PCOS, these TFs represent

promising candidates for involvement in neuroendocrine regulation. These findings

highlight the capacity of our model to identify transcriptional regulators with potential

functional roles in the diverse phenotypic manifestations of PCOS.

Our deep learning-based approach identified 20% of the pcosSNVs as potential

regulatory variants, effectively narrowing down causal variants in loci such as *ERBB4*,

LHCGR, MC4R, etc (Figure S3). For example, among 51 variants in the *ERBB4* locus, we

identified rs79230362 as an enhancer-disrupting variant in HUVEC cells (Table S9). This

variant is in LD with the GWAS SNP rs113168128 and is predicted to disrupt the binding

site of the *ELK1:SREBF2* motif complex (Figure S4). Given the established role of *SREBF2*

in steroidogenesis (52) and the highly cell-type-specific expression of ELK1 in granulosa

cells (Figure S4), this variant likely affects *ERBB4* expression, a key regulator of the oocyte

microenvironment during folliculogenesis (18). Similarly, in the *MC4R* locus, we

identified rs17773430 as a causal enhancer-disrupting variant in WTC11 cells (Table S9).

MC4R is a critical component of the melanocortin pathway and a well-established obesity

susceptibility gene that is also linked to PCOS. Knockout studies of *MC4R* in mice result

in both obesity and infertility phenotypes, highlighting shared regulatory architectures

underlying these conditions (53). rs17773430 is predicted to disrupt the binding site of

TBX2/TBXT, TFs responsible for the development of hypothalamus-pituitary axis (30).

Given that reduced *MC4R* levels are associated with lower LH levels (54), this variant

likely contributes to PCOS etiology through its impact on HPG axis.

On the other hand, multiple reSNVs were identified in the locus of *DENND1A*, *FTO* and

MAPRE1 (Figure S5). The significant overlap of reSNVs in *DENND1A* and *MAPRE1* locus

with active regulatory regions in the fetal brain and WTC11 suggests their potential role

in disease manifestation during early development. Notably, a reSNV in the *MAPRE1*

locus, rs187178, was validated as an enhancer-disrupting variant in the fetal brain and

functions as an eQTL for the neighboring gene *DNMT3B*, which regulates dynamic

methylation transitions during folliculogenesis (24). In total, we identified 12 reSNVs that

have been experimentally validated as enhancer disrupting variants in adipocytes and

fetal brain through MPRA studies (Table S10) (44,45).

Of note, epigenomic data from fetal brain used by the DL model failed to capture the

regulatory impact of pathogenic variants in the *FSHB* locus, including rs10835638 and

rs11031006, which have been experimentally shown to reduce *FSHB* expression

restricted to the pituitary gland (55). This underscores the necessity of incorporating

additional, relevant cell types for a more comprehensive study of the regulatory

landscape of PCOS, when experimental characterization of chromatin marks becomes

available for these cell types.

reSNVs are more likely to exert pleiotropic effects across multiple cell types by

downregulating the expression of their target genes

We further explored the functional impact of reSNVs by examining their association with

gene expression using eQTL data from GTEx. Among reSNVs that also act as eVariants,

hereafter referred to as reVariants, we observed significantly greater enrichment in the

brain, liver, adrenal gland, and pancreas compared to pcosSNVs (Figure 3A), implicating

these tissues as key cell types affected by reSNVs. The proportion of causal cell types

impacted by reVariants was significantly higher than that impacted by otherSNVs (i.e.,

SNVs not prioritized by TREDNet in causal cell types) (Figure 3B, Mann-Whitney p =

5.78×10^{-3}). Within these enriched cell types, reVariants were associated with

significantly stronger downregulation of gene expression relative to otherSNVs, as

measured by normalized effect sizes from GTEx (Figure 3C, Mann-Whitney p =

1.88×10^{-9}). In contrast, no significant difference was observed in gene upregulation

effects (Figure 3C, Mann-Whitney p = 0.91). These findings suggest that reSNVs primarily

exert their regulatory effects through downregulation of gene expression.

The most significant downregulatory effect was observed at the RAB5B–SUOX–RPS26

locus, where reSNVs were linked to reduced expression of RPS26 in multiple cell-types

including the ovary, hypothalamus, and liver. RPS26 is a ubiquitously expressed

ribosomal protein whose downregulation in the ovaries impairs oocyte growth and

premature ovarian failure (56), a hallmark of PCOS. Notably, one reVariant in this region,

rs3741499, which shows a large negative effect size on RPS26 expression (Figure S6), is

predicted to disrupt binding of PROX1 (Table S9), a PCOS risk gene involved in lymphatic

vessel formation around oocytes (57), suggesting a plausible mechanism for impaired

oocyte maturation.

We further investigated pleiotropy by examining the ZBTB16 locus. Although no eQTLs

overlap with variants in this locus, they were predicted to exert strong differential

enhancer activity across multiple cell types (Table S9). Notably, rs1784692, located in an

intron of ZBTB16, demonstrated the highest predicted enhancer-strengthening effect in

the pancreas, adipocytes, WTC11, and liver (Figure 3D, Table S9). The T→C polymorphism

enhances *AR* receptor binding, suggesting a possible association of this locus with cell-

type-specific androgen response functions, such as insulin secretion in the pancreas (58),

and regulation of adipocyte differentiation (59). While ZBTB16 has not been previously

implicated in PCOS, its protein interaction network is enriched for components of

androgen signaling (Figure 3E). These observations suggest that ZBTB16 may act as a

susceptibility locus involved in androgen-mediated regulatory pathways disrupted in

PCOS.

In conclusion, reSNVs prioritized by TREDNet offer valuable insights into disease-

associated regulatory mechanisms and highlight the potential role of risk genes hitherto

uncharacterized in PCOS etiology.

The FTO locus demonstrates disruption of an androgen mediated network pleiotropy

The regulatory locus within the intronic region of *FTO* is a well-known susceptibility locus

with significant implications in obesity and diabetes. Notably, it has been experimentally

validated to function as a distal enhancer of *IRX3*, a TF in PCOS-associated susceptibility

loci (60,61). We hypothesized that this locus may have broader pleiotropic effects across different cell types due to variations in the expression of *IRX3*, which may influence multiple biological pathways (62). Interestingly, the PCOS susceptibility variants localize in the genomic region regulating *IRX3* (chr16:53731249–54975288) (63), suggesting that *IRX3* is likely the target gene of the PCOS susceptibility locus as well (Figure S7).

We identified 12 reSNVs exhibiting significant fold changes across nine cell types (Figure S8). Among these, three variants— rs1421085, rs9940646 and rs9940128—have been validated by MPRA studies to show allelic changes in enhancer activity in mouse preadipocyte and neuronal cell lines (61), further supporting the predictive accuracy of TREDNet in identifying causal variants. Interestingly, we predicted that rs1421085 additionally upregulates enhancer activity in BMEC by potentially modulating the binding site of *ONECUT2* (Figure 4A), a suppressor of androgen receptor signaling which was recently identified as a marker of follicle growth (64,65).

Additionally, we identified another variant within the same locus, rs8050136, which is predicted as a causal variant in the pancreas and liver (Figure 4A, S8). This variant functions as an eQTL for *IRX3* in the pancreas, where IRX3 regulates the conversion of beta to epsilon cells, directly linking it to type 2 diabetes (66). Notably, rs8050136 is also predicted to disrupt the binding site for *ONECUT1*, a transcription factor critical for pancreatic development (Figure 4A). Together, these findings suggest that rs8050136

may serve as another causal variant for type 2 diabetes, possibly preferentially in PCOS

patients.

To address the association of these variants with PCOS, we focused on a previous study

that identified *IRX3* and another gene in this susceptibility locus, *IRX5*, as key regulators

of folliculogenesis in granulosa cells (67). Using evidence from granulosa like cells, BMEC

and HUVEC, we hypothesize that variants in this locus lead to impaired folliculogenesis,

consequently disrupting androgen production in the causal cell type—likely granulosa

cells—through the dysregulated action of *IRX3/IRX5*. This disruption in androgen

production may have pleiotropic effects on other cell types where these genes function

within the androgen-responsive network. In this regard, rs9940128 emerges as a

plausible causal variant as it forms chromatin contacts with promoters of *IRX3* and *IRX5*

(Figure 4B) and is predicted to cause a significant fold change in enhancer activity in

BMEC and HUVEC (Figure S8). Furthermore, the allelic effects of variants in this locus may

also impact *IRX3/5*-mediated functions in hypothalamic neurons (Figure S7), as

demonstrated in mice (61). To explore this further, we analyzed the impact of these

variants in fetal brain and found that rs3751812 is located within binding sites of T-box

family TFs (Figure 4A). Members of the T-box family play a critical role in the commitment

of hypothalamus and pituitary lineages from neuronal precursors (30,68). However,

given the short temporal window of expression of these TFs in neuronal development,

inferring causal mechanisms remains challenging. This highlights the necessity of using

epigenomic datasets across different developmental timepoints for a comprehensive

investigation.

Discussion

Our limited understanding of the regulatory landscape of PCOS stems from its complex

genetic architecture, which presents with heterogeneous phenotypes across different

cell types, individuals, and populations. This complexity has necessitated evolving

diagnostic criteria as our knowledge of the underlying pathophysiology expands. Several

key questions remain unresolved, including the genetic and molecular origins of

reproductive and metabolic dysfunction, the role of androgens and other hormones in

regulatory pathways, and the inheritance patterns affecting both males and females. To

date, GWAS have identified 50 genomic loci associated with PCOS across diverse

populations (Table S2). While the functional significance of genes such as *ERBB4*, *PPARG*,

and *IRX3* has been well established, leading to the use of their agonists as potential

treatments (18,37,67), the precise molecular mechanisms remain elusive. Additionally,

advancements in whole-genome and exome sequencing continue to uncover novel loci,

further complicating our understanding of PCOS and highlighting the need for a deeper

exploration of the core regulatory mechanisms driving its pathophysiology.

Leveraging extensive genetic and epigenetic data, we sought to identify key mechanisms

linking PCOS susceptibility loci to disease etiology. We found that reSNVs prioritized by

our model are significantly enriched for TFBSs associated with folliculogenesis, including

those of WT1, NHLH2, and FOXA1. Notably, reSNVs also show enrichment for the binding

sites of PROX1 and PPARG, both of which are also PCOS risk genes. These findings

underscore the importance of dissecting the underlying gene regulatory networks,

where disruptions at specific nodes (genes) or edges (regulatory interactions) may give

rise to a spectrum of molecular outcomes that contribute to the heterogeneity of PCOS

severity and phenotypic presentation. Our results also highlight the need for further

characterization of TFs, especially those involved in neuronal signaling, such as *TBX21,*

LHX4, etc., along with their interactions with hormonal receptors, to gain deeper insights

into cis- and trans- regulatory mechanisms disrupted in PCOS pathophysiology.

The established role of the HPG axis (69) in regulating circulating reproductive hormone

levels highlights the hypothalamus, pituitary, adrenal gland, and ovarian granulosa and

theca cells as key mediators of PCOS pathophysiology. However, PCOS manifestations

extend beyond the neuroendocrine system, impacting peripheral tissues such as the

pancreas, adipocytes, liver, and heart. This suggests that dysregulation of hormonal

signaling, particularly androgens, may have widespread effects through both direct and

pleiotropic mechanisms. Given the broad expression of the androgen receptor,

disruptions in androgen signaling may contribute to metabolic dysfunctions—such as

insulin resistance and altered adipogenesis—independent of classical reproductive

symptoms like oligomenorrhea. Our findings support this expanded framework and

reveal potential mechanisms by which altered androgen signaling leads to systemic

effects. Accordingly, we propose two categories of pathogenic cell types: (a) primary cell

types, involved directly in steroidogenesis, folliculogenesis, and reproductive hormone

biosynthesis; and (b) secondary cell types, which are affected by the pleiotropic activity

of risk variants or by downstream hormonal dysregulation (Figure S9). By prioritizing

variants that disrupt PCOS relevant TF binding sites at susceptibility loci, we highlight the

importance of TFs interacting with hormone receptors—particularly androgens—as key

modulators of PCOS-related dysfunction.

The identification of multiple reSNVs at several susceptibility loci is suggestive of

regulatory mechanisms wherein one-gene can be regulated by multiple enhancers,

according to which, the expression of a target gene can be influenced by more than one

variant (61,70). For example, two distinct variants in the *FSHB* locus, rs10835638 and

rs11031006, alter *FSHB* expression, ultimately contributing to infertility (55). These

variants may occur in different individuals, leading to distinct, individual-specific

phenotypes depending on the cell-type-specific networks they modulate in a pleiotropic

manner. In addition, the potential pleiotropic impact of disease-associated variants in

non-pathogenic cell types is often buffered by robust regulatory networks, preventing

overt disease manifestation. This suggests that assessing polygenic risk scores may be

necessary to fully understand their contribution to disease susceptibility. Given that

variants in the *FTO* locus have high minor allele frequencies (>0.4), which far exceed the

prevalence of PCOS, it is evident that the disease phenotypes emerge from the

cumulative effects of multiple dysregulated genes and pathways. Further investigations

into polygenic interactions and gene-environment influences will be essential to expand

our understanding of the complexity of PCOS.

The susceptibility loci of PCOS implicate genes such as *ZBTB16*, *AOPEP*, *THADA*, and

CCDC91 (Figure 1A), which are ubiquitously expressed, raising the question of how

disease-specific variants selectively affect certain cell types. At the molecular level,

follicle progression involves signaling pathways like TGFβ, Hippo, Wnt, and mTOR, which

regulate fundamental processes such as cell proliferation, differentiation, and apoptosis

(7). Why, then, do complex diseases manifest in only a subset of susceptible cell types?

In the case of *ZBTB16*, we predicted that rs1784692 strengthens enhancer activity by

increasing the binding affinity of *AR*, thereby implicating *ZBTB16* in downstream

pathways of androgen signaling. This suggests that perturbations in disease-relevant TF

interactions, specific to causal cell types, disrupt molecular networks in a way that

surpasses compensatory mechanisms in other cell types, thereby making certain cells

uniquely vulnerable. Consequently, transcription factors act as primary responders to

disease-associated alterations, preceding the genes they regulate, and may therefore

serve as more informative markers of disease susceptibility than the genes themselves.

Our analysis of the PCOS regulatory landscape reveals unifying molecular mechanisms

underlying disease phenotypes. However, a more comprehensive understanding of gene

regulatory networks requires integrating epigenomic datasets from key pathogenic cell

types—such as the pituitary gland, granulosa, and theca cells, and potentially, the

hypothalamus—across follicular phases to map the spatiotemporal regulation of genes

involved in steroidogenesis and folliculogenesis. Despite the hypothalamus's central role

in the HPG axis, regulatory networks mediated by GnRH signaling remain poorly

understood. Disruptions in this pathway may explain the involvement of risk genes such

as *CNTNAP5*, *ASIC2*, and *CUX2*, potentially linking PCOS to prevalent mental health

disorders (3). Incorporating these datasets can enable the development of more inclusive

deep-learning models capable of predicting regulatory activity changes beyond enhancer

disruptions, offering deeper insights into PCOS pathophysiology.

Additionally, our PCOS subtype classification remains incomplete due to lack of data,

leaving some loci unassigned, which may exclude crucial transcription factors and

interactions essential for understanding regulatory networks. Lastly, our analysis of

causal variants was limited to those occurring within putative enhancers. However,

variants can impact gene regulation beyond enhancer activity. Variants located in

silencers or insulators may disrupt distal enhancer interactions, as observed with IRX3,

emphasizing the need for Hi-C data from pathogenic and affected cell types to resolve

target genes not identifiable through eQTL analysis. Lastly, a comprehensive approach

should also consider the trans-regulatory effects of risk variants—whether through TFs

encoded by susceptibility loci (*PROX1*, *SOX5/8*, *IRF1*) or non-coding RNAs that contribute

to epigenomic regulation of gene expression.

Conclusions

Our results provide valuable insights into molecular mechanisms underlying PCOS

etiology. Future *in vitro* and *in vivo* characterization will be essential to validate these

predictions, potentially paving the way for novel, symptom-targeted therapies for PCOS

patients.

Methods

PCOS susceptibility loci

PCOS GWAS summary statistics were obtained from the NHGRI-GWAS catalog. Variants

in LD were expanded and clustered into 50 loci based on 100kb proximity. Subtypes

identified for 38 GWAS variants (Table S4) were also assigned to their LD variants. The

risk allele from GWAS summary statistic served as the alternate allele for GWAS variants,

while the minor allele from the 1000Genomes catalog was assumed as risk allele for LD

variants. All analyses were conducted using the coordinates and datasets of GRCh38

reference genome.

Transcription factor binding sites

Transcription factor binding site (TFBS) regions were defined by extending variant sites

by 30 bp on each side. TF binding profiles from HOCOMOCO (71) and JASPAR non

redundant collection (72) were analyzed using FIMO with default parameters (73). Aside

from gain and loss of motifs, changes in motif scores were used to assess affinity

differences between reference and alternate alleles. A list of all the TFBSs gained, lost

and modulated for SNPs exhibiting significant fold change is provided in Table S9.

Cell type specific DL models

We used a two phase TREDNet model developed in our lab for cell-type specific enhancer

prediction (74). The first phase of the model was pre-trained on 4560 genomic and

epigenomic profiles, which included DHS, ATAC-Seq, Histone ChIP-Seq and and TF ChIP-

Seq peaks from ENCODE v4 (75). The second phase was fine-tuned to predict cell type

specific enhancers using training datasets described below. Chromosomes 8 and 9 were

held out for testing, chromosome 6 was used for validation and other autosomal

chromosomes were used to build the second phase model. The area under the ROC and

PRC curve for each of these models is provided in Figure 2A. The pre-trained phase-one

model has been deposited at https://doi.org/10.5281/zenodo.8161621.

Open chromatin (DHS or ATAC-Seq) and H3K27ac profiles for the causal cell-types were

downloaded from ENCODE (75) (Table S8). Positive datasets were defined as 2 kb regions

centered on DHS or ATAC-Seq peaks overlapping with H3K27ac (or H3K4me1 in fetal

brain) peaks of each cell type, excluding coding sequences, promoter proximal regions (

<2kb from TSS) and ENCODE blacklisted regions (76). A 10-fold control dataset was

generated for each cell-type using randomly sampled 2kb fragments of the genome,

excluding the positive dataset of that cell type and blacklisted regions.

Each 2 kb fragment received an enhancer probability score. Active enhancers were

predicted at a 10% FPR with a 1:10 positive-to-control ratio. Variant effects were assessed

by scoring 2 kb regions centered on each variant for reference and alternate alleles. A

significant enhancer activity change was defined as an alternate/reference score ratio

>1.2 or <0.8.

Enrichment analysis of TFBSs

We used command line FIMO (77) to scan vertebrate TF motifs from JASPAR (78) and

HOCOMOCO (79) databases along the sequences, applying a p-value threshold of 10^{-5}.

To identify TFs enriched in the loci of pcosSNVs, we generated a background set of SNVs

by extracting all variants from the 1000 Genomes Project within a 50 kb flanking region

of each pcosSNV. After excluding the pcosSNVs themselves and removing duplicates, this

resulted in a non-redundant background set of approximately 71,000 SNVs. Differential

enrichment of TFBSs between the metabolic and reproductive subtypes was assessed

using a binomial test, with normalized counts of a TF overlapping variants of one subtype

analyzed against the normalized counts of the same TF overlapping variants of the other

subtype as the background.

GWAS trait enrichment

Summary statistics for 25,649 traits were downloaded from the NHGRI-GWAS catalog.

Linkage disequilibrium (LD) variants for each GWAS SNP were identified using PLINK

(v1.9(80)) with an r^2 threshold of ≥ 0.8. Traits with at least 1,000 combined GWAS and LD

variants were retained for downstream enrichment analysis in reproductive and

metabolic SNV categories.

Data and tools

The H3K27ac peaks for KGN cells and adipocytes were sourced from literature (81,82).

The KGN wig file was converted to NarrowPeak format using UCSC BigWig tools (83) and

MACS peak calling software (84).

Motif logos were retrieved from HOCOMOCO database (79). Ontology enrichment of

pcosSNVs was performed using the Molecular Signatures Database (85). Protein

interaction networks and enriched pathways (Figure 3E) were obtained from STRING

database (86).

Evolutionary conservation of genomic regions was measured by their extent of overlap

with   phastCons   elements   conserved   across   30   primates

(https://hgdownload.soe.ucsc.edu/goldenPath/hg38/database/

phastConsElements30way.txt.gz).

Acknowledgements

Data availability

Please see the section "Data and tools" and supplementary tables. The deep learning

models for eleven cell-types trained in the study are deposited at

https://doi.org/10.5281/zenodo.15041688.

Funding

This research was supported by the Division of Intramural Research of the National

Library of Medicine (NLM), National Institutes of Health.

Authors' contributions

J.S. performed the computational analysis, analyzed the data, and prepared figures and

tables. I.O. supervised the study. J.S. and I.O. wrote the

manuscript.

References

1.   Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. Polycystic ovary
syndrome. Lancet Diabetes Endocrinol. 2022 Sep 1;10(9):668–80.

2.   Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary
syndrome: a comprehensive review. Hum Reprod Update. 2021 Apr 21;27(3):584–618.

3.   Stener-Victorin E, Teede H, Norman RJ, Legro R, Goodarzi MO, Dokras A, et al. Polycystic ovary
syndrome. Nat Rev Dis Primer. 2024 Apr 18;10(1):1–23.

4.   Zaidi M, Yuen T, Kim SM. Pituitary crosstalk with bone, adipose tissue and brain. Nat Rev
Endocrinol. 2023 Dec;19(12):708–21.

5.   McCartney CR, Marshall JC. Polycystic Ovary Syndrome. N Engl J Med. 2016 Jul 7;375(1):54–64.

6.   Abedel-Majed MA, Romereim SM, Davis JS, Cupp AS. Perturbations in Lineage Specification of
Granulosa and Theca Cells May Alter Corpus Luteum Formation and Function. Front Endocrinol
[Internet]. 2019 [cited 2023 Dec 15];10. Available from:
https://www.frontiersin.org/articles/10.3389/fendo.2019.00832

7.   Wang K, Li Y. Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome.
Front Endocrinol. 2023;14:1191759.

8.   Liao B, Qiao J, Pang Y. Central Regulation of PCOS: Abnormal Neuronal-Reproductive-Metabolic
Circuits in PCOS Pathophysiology. Front Endocrinol. 2021;12:667422.

9.   Zhang CH, Liu XY, Wang J. Essential Role of Granulosa Cell Glucose and Lipid Metabolism on
Oocytes and the Potential Metabolic Imbalance in Polycystic Ovary Syndrome. Int J Mol Sci. 2023
Nov 13;24(22):16247.

10. Dapas M, Dunaif A. Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms
and Classification. Endocr Rev. 2022 Nov 25;43(6):927–65.

11. Gorsic LK, Dapas M, Legro RS, Hayes MG, Urbanek M. Functional Genetic Variation in the Anti-
Müllerian Hormone Pathway in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab.
2019 Feb 20;104(7):2855–74.

12. Caburet S, Fruchter RB, Legois B, Fellous M, Shalev S, Veitia RA. A homozygous mutation of GNRHR
in a familial case diagnosed with polycystic ovary syndrome. Eur J Endocrinol. 2017
May;176(5):K9–14.

13. Chen Y, Wang G, Chen J, Wang C, Dong X, Chang HM, et al. Genetic and Epigenetic Landscape for
Drug Development in Polycystic Ovary Syndrome. Endocr Rev. 2024 Jul 12;45(4):437–59.

14. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a
Dutch twin-family study. J Clin Endocrinol Metab. 2006 Jun;91(6):2100–4.

15. Wang F, Pan J, Liu Y, Meng Q, Lv P, Qu F, et al. Alternative splicing of the androgen receptor in
polycystic ovary syndrome. Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4743–8.

16. Muccee F, Ashraf NM, Razak S, Afsar T, Hussain N, Husain FM, et al. Exploring the association of
ESR1 and ESR2 gene SNPs with polycystic ovary syndrome in human females: a comprehensive
association study. J Ovarian Res. 2024 Jan 29;17(1):27.

17. Mathieson I. The omnigenic model and polygenic prediction of complex traits. Am J Hum Genet.
2021 Sep 2;108(9):1558–63.

18. Veikkolainen V, Ali N, Doroszko M, Kiviniemi A, Miinalainen I, Ohlsson C, et al. Erbb4 regulates the
oocyte microenvironment during folliculogenesis. Hum Mol Genet. 2020 Oct 10;29(17):2813–30.

19. LaVoie HA. The GATA-keepers of ovarian development and folliculogenesis. Biol Reprod. 2014
Aug;91(2):38.

20. Waterbury JS, Teves ME, Gaynor A, Han AX, Mavodza G, Newell J, et al. The PCOS GWAS Candidate
Gene ZNF217 Influences Theca Cell Expression of DENND1A.V2, CYP17A1, and Androgen
Production. J Endocr Soc. 2022 Jul 1;6(7):bvac078.

21. Li M, Zhao H, Zhao SG, Wei DM, Zhao YR, Huang T, et al. The HMGA2-IMP2 Pathway Promotes
Granulosa Cell Proliferation in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019 Apr
1;104(4):1049–59.

22. Xi Y, Shen W, Ma L, Zhao M, Zheng J, Bu S, et al. HMGA2 promotes adipogenesis by activating
C/EBPβ-mediated expression of PPARγ. Biochem Biophys Res Commun. 2016 Apr 15;472(4):617–
23.

23. Arnold M, Raffler J, Pfeufer A, Suhre K, Kastenmüller G. SNiPA: an interactive, genetic variant-
centered annotation browser. Bioinforma Oxf Engl. 2015 Apr 15;31(8):1334–6.

24. Zhang Y, Yan Z, Qin Q, Nisenblat V, Chang HM, Yu Y, et al. Transcriptome Landscape of Human
Folliculogenesis Reveals Oocyte and Granulosa Cell Interactions. Mol Cell. 2018 Dec 20;72(6):1021-
1034.e4.

25. Dapas M, Lin FTJ, Nadkarni GN, Sisk R, Legro RS, Urbanek M, et al. Distinct subtypes of polycystic
ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis.
PLoS Med. 2020 Jun 23;17(6):e1003132.

26. van der Ham K, Moolhuijsen LME, Brewer K, Sisk R, Dunaif A, Laven JSE, et al. Clustering Identifies
Subtypes With Different Phenotypic Characteristics in Women With Polycystic Ovary Syndrome.
[cited 2025 Apr 15]; Available from: https://dx.doi.org/10.1210/clinem/dgae298

27. Hunter AL, Pelekanou CE, Barron NJ, Northeast RC, Grudzien M, Adamson AD, et al. Adipocyte
NR1D1 dictates adipose tissue expansion during obesity. Tontonoz P, James DE, editors. eLife. 2021
Aug 5;10:e63324.

28. Evans RM, Mangelsdorf DJ. Nuclear Receptors, RXR, and the Big Bang. Cell. 2014 Mar
27;157(1):255–66.

29. Li D, Chen J, Yun C, Li X, Huang Z. MiR-122–5p regulates the pathogenesis of childhood obesity by
targeting CPEB1. Obes Res Clin Pract. 2022 May 1;16(3):206–13.

30. Pontecorvi M, Goding CR, Richardson WD, Kessaris N. Expression of Tbx2 and Tbx3 in the
developing hypothalamic-pituitary axis. Gene Expr Patterns GEP. 2008 Jul;8(6):411–7.

31. Candelaria NR, Richards JS. Targeted deletion of NR2F2 and VCAM1 in theca cells impacts ovarian
follicular development: insights into polycystic ovary syndrome?†. Biol Reprod. 2024 Apr
1;110(4):782–97.

32. GTEx Consortium, Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis Working
Group, Statistical Methods groups—Analysis Working Group, Enhancing GTEx (eGTEx) groups, NIH
Common Fund, NIH/NCI, et al. Genetic effects on gene expression across human tissues. Nature.
2017 Oct 11;550(7675):204–13.

33. Bai Y, Dai X, Harrison AP, Chen M. RNA regulatory networks in animals and plants: a long
noncoding RNA perspective. Brief Funct Genomics. 2015 Mar;14(2):91–101.

34. Fairfax BP, Makino S, Radhakrishnan J, Plant K, Leslie S, Dilthey A, et al. Genetics of gene
expression in primary immune cells identifies cell type-specific master regulators and roles of HLA
alleles. Nat Genet. 2012 Mar 25;44(5):502–10.

35. Sonawane AR, Platig J, Fagny M, Chen CY, Paulson JN, Lopes-Ramos CM, et al. Understanding
Tissue-Specific Gene Regulation. Cell Rep. 2017 Oct 24;21(4):1077–88.

36. Han L, Shen WJ, Bittner S, Kraemer FB, Azhar S. PPARs: regulators of metabolism and as
therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. Future Cardiol. 2017
May;13(3):279–96.

37. Kim J, Bagchi IC, Bagchi MK. Control of ovulation in mice by progesterone receptor-regulated gene
networks. Mol Hum Reprod. 2009 Dec;15(12):821–8.

38. Zhou J, Theesfeld CL, Yao K, Chen KM, Wong AK, Troyanskaya OG. Deep learning sequence-based
ab initio prediction of variant effects on expression and disease risk. Nat Genet. 2018
Aug;50(8):1171–9.

39. Avsec Ž, Agarwal V, Visentin D, Ledsam JR, Grabska-Barwinska A, Taylor KR, et al. Effective gene
expression prediction from sequence by integrating long-range interactions. Nat Methods. 2021
Oct;18(10):1196–203.

40. Hudaiberdiev S, Taylor DL, Song W, Narisu N, Bhuiyan RM, Taylor HJ, et al. Modeling islet
enhancers using deep learning identifies candidate causal variants at loci associated with T2D and
glycemic traits. Proc Natl Acad Sci U S A. 2023 Aug 29;120(35):e2206612120.

41. Li S, Hannenhalli S, Ovcharenko I. De novo human brain enhancers created by single-nucleotide
mutations. Sci Adv. 2023 Feb 15;9(7):eadd2911.

42. Antczak M, Van Blerkom J. The vascular character of ovarian follicular granulosa cells: phenotypic
and functional evidence for an endothelial-like cell population. Hum Reprod Oxf Engl. 2000
Nov;15(11):2306–18.

43. Hartanti MD, Rosario R, Hummitzsch K, Bastian NA, Hatzirodos N, Bonner WM, et al. Could
perturbed fetal development of the ovary contribute to the development of polycystic ovary
syndrome in later life? PloS One. 2020;15(2):e0229351.

44. Joslin AC, Sobreira DR, Hansen GT, Sakabe NJ, Aneas I, Montefiori LE, et al. A functional genomics
pipeline identifies pleiotropy and cross-tissue effects within obesity-associated GWAS loci. Nat
Commun. 2021 Sep 6;12(1):5253.

45. Deng C, Whalen S, Steyert M, Ziffra R, Przytycki PF, Inoue F, et al. Massively parallel
characterization of regulatory elements in the developing human cortex. Science. 2024 May
24;384(6698):eadh0559.

46. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, et al. FoxA1 translates epigenetic
signatures into enhancer-driven lineage-specific transcription. Cell. 2008 Mar 21;132(6):958–70.

47. Mullen RD, Colvin SC, Hunter CS, Savage JJ, Walvoord EC, Bhangoo APS, et al. Roles of the LHX3
and LHX4 LIM-homeodomain factors in pituitary development. Mol Cell Endocrinol. 2007 Feb
1;265–266:190–5.

48. Topaloglu AK, Simsek E, Kocher MA, Mammadova J, Bober E, Kotan LD, et al. Inactivating NHLH2
variants cause idiopathic hypogonadotropic hypogonadism and obesity in humans. Hum Genet.
2022 Feb;141(2):295–304.

49. Cen C, Chen M, Zhou J, Zhang L, Duo S, Jiang L, et al. Inactivation of Wt1 causes pre-granulosa cell
to steroidogenic cell transformation and defect of ovary development†. Biol Reprod. 2020 Jun
23;103(1):60–9.

50. Li X, Wu X, Zhang H, Liu P, Xia L, Zhang N, et al. Analysis of single-cell RNA sequencing in human
oocytes with diminished ovarian reserve uncovers mitochondrial dysregulation and translation
deficiency. Reprod Biol Endocrinol. 2024 Nov 15;22(1):146.

51. Zhang Y, Federation AJ, Kim S, O'Keefe JP, Lun M, Xiang D, et al. Targeting nuclear receptor NR4A1-
dependent adipocyte progenitor quiescence promotes metabolic adaptation to obesity. J Clin
Invest. 2018 Nov 1;128(11):4898–911.

52. Nakanishi T, Tanaka R, Tonai S, Lee JY, Yamaoka M, Kawai T, et al. LH Induces De Novo Cholesterol
Biosynthesis via SREBP Activation in Granulosa Cells During Ovulation in Female Mice.
Endocrinology. 2021 Nov 1;162(11):bqab166.

53. Rajae TalbiTodd L StincicKaitlin FerrariChoi Ji HaeKarol WalecElizabeth MedveAchi GerutshangSilvia
LeónElizabeth A McCarthyOline K RønnekleivMartin J KellyVíctor M Navarro2024POMC neurons
control fertility through differential signaling of MC4R in Kisspeptin neurons. eLife13:RP100722.

54. Villa PA, Ruggiero-Ruff RE, Jamieson BB, Campbell RE, Coss D. Obesity Alters POMC and Kisspeptin
Neuron Cross Talk Leading to Reduced Luteinizing Hormone in Male Mice. J Neurosci Off J Soc
Neurosci. 2024 Jul 10;44(28):e0222242024.

55. Bohaczuk SC, Thackray VG, Shen J, Skowronska-Krawczyk D, Mellon PL. FSHB Transcription is
Regulated by a Novel 5' Distal Enhancer With a Fertility-Associated Single Nucleotide
Polymorphism. Endocrinology. 2021 Jan 1;162(1):bqaa181.

56. Liu XM, Yan MQ, Ji SY, Sha QQ, Huang T, Zhao H, et al. Loss of oocyte Rps26 in mice arrests oocyte
growth and causes premature ovarian failure. Cell Death Dis. 2018 Nov 19;9(12):1–15.

57. Svingen T, François M, Wilhelm D, Koopman P. Three-Dimensional Imaging of Prox1-EGFP
Transgenic Mouse Gonads Reveals Divergent Modes of Lymphangiogenesis in the Testis and Ovary.
PLOS ONE. 2012 Dec 20;7(12):e52620.

58. Karagiannopoulos A, Westholm E, Ofori JK, Cowan E, Esguerra JLS, Eliasson L. Glucocorticoid-
mediated induction of ZBTB16 affects insulin secretion in human islets and EndoC-βH1 β-cells.
iScience. 2023 May 19;26(5):106555.

59. Sun L, Ji S, Xie X, Si L, Liu S, Lin Y, et al. Deciphering the interaction between Twist1 and PPARγ
during adipocyte differentiation. Cell Death Dis. 2023 Nov 23;14(11):764.

60. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gómez-Marín C, et al. Obesity-associated
variants within FTO form long-range functional connections with IRX3. Nature. 2014 Mar
20;507(7492):371–5.

61. Sobreira DR, Joslin AC, Zhang Q, Williamson I, Hansen GT, Farris KM, et al. Extensive pleiotropism
and allelic heterogeneity mediate metabolic effects of IRX3 and IRX5. Science. 2021 Jun
4;372(6546):1085–91.

62. Brynedal B, Choi J, Raj T, Bjornson R, Stranger BE, Neale BM, et al. Large-Scale trans-eQTLs Affect
Hundreds of Transcripts and Mediate Patterns of Transcriptional Co-regulation. Am J Hum Genet.
2017 Apr 6;100(4):581–91.

63. Claussnitzer M, Dankel SN, Kim KH, Quon G, Meuleman W, Haugen C, et al. FTO Obesity Variant
Circuitry and Adipocyte Browning in Humans. N Engl J Med. 2015 Sep 3;373(10):895–907.

64. Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, et al. ONECUT2 is a targetable
master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med. 2018
Dec;24(12):1887–98.

65. Zhao, ZH., Meng, TG., Chen, XY. et al. Spatiotemporal and single-cell atlases to dissect regional
specific cell types of the developing ovary. Commun Biol 8, 849 (2025).
https://doi.org/10.1038/s42003-025-08277-4

66. Ragvin A, Moro E, Fredman D, Navratilova P, Drivenes Ø, Engström PG, et al. Long-range gene
regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3. Proc
Natl Acad Sci U S A. 2010 Jan 12;107(2):775–80.

67. Fu A, Koth ML, Brown RM, Shaw SA, Wang L, Krentz KJ, et al. IRX3 and IRX5 collaborate during ovary development and follicle formation to establish responsive granulosa cells in the adult mouse†. Biol Reprod. 2020 Aug 21;103(3):620–9.

68. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, et al. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 2001 Mar 23;104(6):849–59.

69. Dai R, Sun Y. Altered GnRH neuron-glia networks close to interface of polycystic ovary syndrome: Molecular mechanism and clinical perspectives. Life Sci. 2025 Jan 15;361:123318.

70. Corradin O, Saiakhova A, Akhtar-Zaidi B, Myeroff L, Willis J, Cowper-Sal lari R, et al. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 2014 Jan;24(1):1–13.

71. Kulakovskiy IV, Vorontsov IE, Yevshin IS, Sharipov RN, Fedorova AD, Rumynskiy EI, et al. HOCOMOCO: towards a complete collection of transcription factor binding models for human and mouse via large-scale ChIP-Seq analysis. Nucleic Acids Res. 2018 Jan 4;46(D1):D252–9.

72. Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2023 Nov 14;gkad1059.

73. Bailey TL, Johnson J, Grant CE, Noble WS. The MEME Suite. Nucleic Acids Res. 2015 Jul 1;43(W1):W39–49.

74. Hudaiberdiev S, Taylor DL, Song W, Narisu N, Bhuiyan RM, Taylor HJ, et al. Modeling islet enhancers using deep learning identifies candidate causal variants at loci associated with T2D and glycemic traits. Proc Natl Acad Sci U S A. 2023 Aug 29;120(35):e2206612120.

75. Luo Y, Hitz BC, Gabdank I, Hilton JA, Kagda MS, Lam B, et al. New developments on the Encyclopedia of DNA Elements (ENCODE) data portal. Nucleic Acids Res. 2020 Jan 8;48(D1):D882–9.

76. Amemiya HM, Kundaje A, Boyle AP. The ENCODE Blacklist: Identification of Problematic Regions of the Genome. Sci Rep. 2019 Jun 27;9(1):9354.

77. Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. Bioinformatics. 2011 Apr 1;27(7):1017–8.

78. Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2024 Jan 5;52(D1):D174–82.

79. Vorontsov IE, Eliseeva IA, Zinkevich A, Nikonov M, Abramov S, Boytsov A, et al. HOCOMOCO in 2024: a rebuild of the curated collection of binding models for human and mouse transcription factors. Nucleic Acids Res. 2024 Jan 5;52(D1):D154–63.

80. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A Tool Set for
Whole-Genome Association and Population-Based Linkage Analyses. Am J Hum Genet. 2007
Sep;81(3):559–75.

81. Hazell Pickering S, Abdelhalim M, Collas P, Briand N. Alternative isoform expression of key
thermogenic genes in human beige adipocytes. Front Endocrinol. 2024;15:1395750.

82. Weis-Banke SE, Lerdrup M, Kleine-Kohlbrecher D, Mohammad F, Sidoli S, Jensen ON, et al. Mutant
FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors. Cancer Res.
2020 Sep 1;80(17):3466–79.

83. Kent WJ, Zweig AS, Barber G, Hinrichs AS, Karolchik D. BigWig and BigBed: enabling browsing of
large distributed datasets. Bioinformatics. 2010 Sep 1;26(17):2204–7.

84. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based Analysis of
ChIP-Seq (MACS). Genome Biol. 2008 Sep 17;9(9):R137.

85. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular
signatures database (MSigDB) 3.0. Bioinformatics. 2011 Jun 15;27(12):1739–40.

86. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in
2023: protein-protein association networks and functional enrichment analyses for any sequenced
genome of interest. Nucleic Acids Res. 2023 Jan 6;51(D1):D638–46.

Figure 1: (A) PCOS susceptibility loci and their distribution in non-coding regions, (B) Gene Ontology annotations of target genes, (C) Fold enrichment of PCOS eVariants in GTEx cell-types (reported eVariants with enrichment binomial p-value < 0.01).

Figure 2: (A) ROC and PRC curves of eleven cell-type specific TREDNet models, (B) A comparison of fold change (alternate / reference allele) in TREDNet scores between all variants and those exhibiting significant change in enhancer activity in MPRA, using Wilcoxon test (C) Fraction of SNVs overlapping with phastCons elements conserved across 30 primates, (D) TFs enriched among reSNVs compared with control SNVs (hypergeometric p-value < 0.01). (ns: p > 0.05, *: p <= 0.05,**: p <= 0.01,***: p <= 0.001)

786
Figure 3: Regulatory impact of reSNVs prioritized by TREDNet. (A) Fold enrichment of reSNVs compared to pcosSNVs across cell-types
(binomial p < 0.01). (B) Comparison of the number of GTEx cell-types impacted by reSNVs versus otherSNVs, (C) Normalized effect size of
reSNVs versus otherSNVs. Left and right panels show differences for downregulating (NES ≤ −0.5) and upregulating (NES ≥ 0.5) variants,
respectively. (D) Genomic overlap of an intronic reSNV (rs1784692) at the ZBTB16 locus with epigenomic features from cell types where
it exhibits predicted allele-specific activity. The affected Androgen Receptor (AR) motif is shown below. (E) Functional enrichment of

Figure 4: reSNVs in FTO locus exhibiting significant fold change in TREDNet predicted enhancer activity. (A) Overlap of reSNVs with active
regulatory regions of pathogenic cell-types (B) Intact Hi-C map of chromatin interactions from reSNVs in FTO locus in HUVEC
(doi:10.17989/ENCSR788FBI)